(MENAFN- GlobeNewsWire - Nasdaq) The CAR-T Cell Therapy Market is expanding due to its high efficacy in hematological malignancies and emerging solid tumor indications. Key opportunities include advancing therapeutic applications, overcoming cost barriers for wider access, and capitalizing on substantial R&D investments.

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets's offering.
The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030.

Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.

Key Market Drivers
The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.
Key Market Challenges
The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.
Key Market Trends
Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy.
However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.

Key Attributes:

Report Attribute	Details
No. of Pages	182
Forecast Period	2024 - 2030
Estimated Market Value (USD) in 2024	$3.87 Billion
Forecasted Market Value (USD) by 2030	$13.25 Billion
Compound Annual Growth Rate	22.7%
Regions Covered	Global

Report Scope:

Key Market Players Profiled:

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Cellectis SA
• Amgen Inc.
• Pfizer Inc
• Merck KgaA
• Intellia Therapeutics, Inc.
• Johnson & Johnson

By Product Type:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Abecma

By Tumor Type:

• Hematological Malignancies
• Solid Tumors

By Indication:

• Diffused Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Others

By Targeted Antigen:

• D 19
• BCMA (B-Cell Maturation Antigen)
• Others

By End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Treatment Type:

• Single Treatment
• Combination Treatment

By Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• CAR-T Cell Therapy Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN01122025004107003653ID1110419958